Disease: Gram-positive bacterial infections
Global 2013-14 sales: $1.35 billion
U.S. patent expiration date: May 2015
Pfizer's ($PFE) Zyvox revenues in the U.S. grew last year, but that may not be the case come its 2015 patent expiration. Currently the world's best-selling branded agent used to treat serious Gram-positive pathogens, Zyvox recorded a 1% revenue uptick in 2013 primarily due to increased demand in both the U.S. and Europe.
One generics maker has already presented a challenge: Last February, Apotex notified Pfizer that it had filed an ANDA with the FDA for a copy, asserting the invalidity of Zyvox's basic patent. The following month, the pharma giant hit back, filing an action against Apotex in district court for patent infringement. In December the action was settled, Pfizer said in its annual report.
Pfizer to pay $3.3M to settle Zyvox probe
FDA warns against imaging med, flags Zyvox interaction
-- Carly Helfand (email | Twitter)